Drug intelligence / Profile preview

CHF1035

Development stage: Preclinical
Lead developer: Chiesi
Modality: Small Molecules
Administration: Ophthalmic

Overview

CHF1035 is a small molecule dual agonist of the dopamine D2 receptor and the alpha-2 adrenergic receptor. Developed by Chiesi Farmaceutici, it is a racemic mixture of the enantiomers CHF1800 (+) and CHF1810 (-). The compound and its metabolite, CHF1024, have demonstrated significant and prolonged intraocular pressure (IOP) lowering effects in preclinical rabbit models, suggesting potential utility in the treatment of glaucoma and ocular hypertension. Its duration of action appears superior to brimonidine in animal studies, without the contralateral eye effects observed with some other ocular hypotensives.

Targets

ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on CHF1035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHF1035.

Explore the full profile